Intra-Cellular Therapies

World Rank (Jan-05-2024)

2,318

Market Cap (Jan-05-2024)

6.689 Billion USD

World Rank (Jul-30-2023)

2,600

Market Cap (Jul-30-2023)

5.833 Billion USD

World Rank (Jan-07-2022)

4,331

Market Cap (Jan-07-2022)

3.505 Billion USD

World Rank (Jan-01-2021)

4,749

Market Cap (Jan-01-2021)

2.549 Billion USD

Company Rank in Country in 2023

Rank in USA in July-2023 is 881

Headquarters Country

USA

Nasdaq / NYSE Code

ITCI

Employee Count

561

Employee Count as of Date

As on 2022

Headquarters City/State

New York

World Region

Americas

World Subregion

Northern America

Annual Revenue in USD

249 Million USD

Annual Operating Income in USD

-263 Million USD

Annual Net Income in USD

-256 Million USD

Annual Results for Period Ending

Dec-2022 ending year

Total Assets in USD

754 Million USD

Total Liabilities in USD

98 Million USD

Total Equity in USD

656 Million USD

Balance Sheet for Period Ending

Dec-2022 ending year

Business Sector

Company Website

INTRA-CELLULAR THERAPIES

Yahoo

Yahoo @ Nasdaq

Company Profile

Intra-Cellular Therapies is a Biopharmaceutical company. It develops innovative treatments to improve the lives of individuals suffering from neuropsychiatric and neurologic disorders in order to reduce the burden on patients and their caregivers. The headquarters is in USA.

Annual Results Summary

INTRA-CELLULAR THERAPIES - Yearly Revenue and Net Income - in Million USD:

Year - Ending	Revenue	Operating Income	Net Income
Dec-2022	249	-263 (Loss)	-256 (Loss)
Dec-2021	81	-285 (Loss)	-284 (Loss)
Dec-2020	22	-231 (Loss)	-227 (Loss)
Dec-2019	60	-153 (Loss)	-147 (Loss)